Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?
Current Treatment Options in Oncology · 2024
DOI: 10.1007/s11864-024-01200-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2024. Verfasst von Alexander F Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Immunotherapy, Tumor Microenvironment. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 111 Literaturangaben.
Abstract (Originalsprache)
OPINION STATEMENT: Immunotherapy for glioblastoma (GBM) remains an intensive area of investigation. Given the seismic impact of cancer immunotherapy across a range of malignancies, there is optimism that harnessing the power of immunity will influence GBM as well. However, despite several phase 3 studies, there are still no FDA-approved immunotherapies for GBM. Importantly, the field has learned a great deal from the randomized studies to date. Today, we are continuing to better understand the disease-specific features of the microenvironment in GBM-as well as the exploitable antigenic characteristic of the tumor cells themselves-that are informing the next generation of immune-based therapeutic strategies. The coming phase of next-generation immunotherapies is thus poised to bring us closer to treatments that will improve the lives of patients with GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
- Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
- Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
- Department of Neurosurgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA. gpdunn@mgh.harvard.edu.
- Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. gpdunn@mgh.harvard.edu.
Zitieren
APA
Wang, A. F., Hsueh, B., Choi, B. D., Gerstner, E. R., & Dunn, G. P. (2024). Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-024-01200-9
Vancouver
Wang AF, Hsueh B, Choi BD, Gerstner ER, Dunn GP. Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?. Current Treatment Options in Oncology. 2024. doi:10.1007/s11864-024-01200-9
BibTeX
@article{Wang2024,
author = {Wang, Alexander F and Hsueh, Brian and Choi, Bryan D and Gerstner, Elizabeth R and Dunn, Gavin P},
title = {Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?},
journal = {Current Treatment Options in Oncology},
year = {2024},
doi = {10.1007/s11864-024-01200-9}
}
EUVIMED